MyoKardia, Inc. (MYOK) Downgraded by Zacks Investment Research
According to Zacks, “MyoKardia, Inc. is a biopharmaceutical company. The company focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its product candidate consists of MYK-461, a small molecule to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy, DCM-1, treats heritable dilated cardiomyopathy by restoring normal contractility in the diseased DCM heart, HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients and LUS-1, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart, which are in different clinical trial. MyoKardia, Inc. is headquartered in San Francisco, California. “
MYOK has been the subject of a number of other research reports. Wells Fargo & Company restated a buy rating on shares of MyoKardia in a research report on Thursday, September 22nd. Wedbush restated an outperform rating and set a $22.00 target price (down previously from $24.00) on shares of MyoKardia in a research report on Wednesday, September 28th. Finally, Cowen and Company restated a buy rating and set a $28.00 target price on shares of MyoKardia in a research report on Tuesday, November 8th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $23.00.
Shares of MyoKardia (NASDAQ:MYOK) traded up 3.76% during midday trading on Tuesday, reaching $13.80. The company had a trading volume of 14,568 shares. MyoKardia has a 52-week low of $6.24 and a 52-week high of $22.83. The company’s 50-day moving average is $14.92 and its 200-day moving average is $16.42. The firm’s market cap is $433.71 million.
MyoKardia (NASDAQ:MYOK) last released its earnings results on Monday, November 7th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by $0.28. The firm had revenue of $3.55 million for the quarter, compared to the consensus estimate of $4.83 million. MyoKardia had a negative return on equity of 43.41% and a negative net margin of 248.75%. The business’s quarterly revenue was up .0% compared to the same quarter last year. Equities research analysts expect that MyoKardia will post ($1.50) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “MyoKardia, Inc. (MYOK) Downgraded by Zacks Investment Research” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US & international copyright laws. The correct version of this article can be viewed at http://www.watchlistnews.com/myokardia-inc-myok-downgraded-by-zacks-investment-research/1059953.html.
Several large investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company bought a new stake in shares of MyoKardia during the third quarter worth approximately $143,000. Spark Investment Management LLC bought a new stake in shares of MyoKardia during the second quarter worth approximately $150,000. D. E. Shaw & Co. Inc. bought a new stake in shares of MyoKardia during the third quarter worth approximately $258,000. Credit Suisse AG bought a new stake in shares of MyoKardia during the third quarter worth approximately $285,000. Finally, Teachers Advisors Inc. boosted its stake in shares of MyoKardia by 185.7% in the second quarter. Teachers Advisors Inc. now owns 18,223 shares of the company’s stock worth $226,000 after buying an additional 11,845 shares during the period. 45.21% of the stock is owned by institutional investors and hedge funds.
MyoKardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that results from biomechanical defects in cardiac muscle contraction. It is engaged in the business of developing and commercializing therapeutics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.